Levodopa therapeutics for Parkinson's disease: new developments

Parkinsonism and Related Disorders

Volumn 15, Issue 1, 2009, Pages

  LeWitt, Peter A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Anti parkinsonian therapy; Levodopa; New delivery system

Indexed keywords

ANTIPARKINSON AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 58149141585     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70009-4     Document Type: Article

References (39)

1. LeWitt P.A. The pharmacology of levodopa in treatment of Parkinson disease: an update. In: Calne D.B. (Ed). Drugs for the treatment of Parkinson's disease. Handbook of experimental pharmacology 88 (1989), Springer-Verlag, Berlin 325-384
2. Sachs O. Awakenings (1974), Doubleday, Garden City, NY
3. Merello M., Nouzeilles M.I., Arce G.P., and Leiguarda R. Accuracy of acute levodopa challenge for clinical prediction of sustained long- term levodopa response as a major criterion for idiopathic Parkinson's disease. Mov Disord 17 (2002) 795-798
4. Carlsson A., Lindqvist M., and Magmusson T. 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature (London) 180 (1957) 1200
5. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 17 (2002) 501-508
6. Cotzias G.C., Van Woert M., and Shifter L. Aromatic amino acids and modification of parkinsonism. N Engl J Med 276 (1967) 374-379
7. Cotzias G.C., Papavasiliou P.S., and Gellene R. Modification of parkinsonism-chronic treatment with l-DOPA. N Engl J Med 280 (1969) 337-345
8. Nelson M.V., Berchou R.B., and LeWitt P.A. Parkinson's disease. In: DiPiro J.T., Talbert R.L., Yee G.C., Matzke G.R., Wells B.G., and Posey L.M. (Eds). Pharmacotherapy: A pathophysiologic approach. 5th ed. (2005), Appleton & Lange, Stamford, CT 1089-1102
9. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
10. Nutt J.G., and Fellman J.H. Pharmacokinetics of levodopa. Clin Neuropharmacol 7 (1984) 35-49
11. Nutt J.G., Woodward W.R., and Anderson J.L. Effect of carbidopa on pharmacokinetics of intravenously administered levodopa: implications for mechanism of action of carbidopa in the treatment of Parkinsonism. Ann Neurol 13 (1985) 537-544
12. Cedarbaum J.M., Kutt H., Dhar A.K., Watkins S., and McDowell F.H. Effect of supplemental carbidopa on the bioavailability of l-dopa. Clin Neuropharmacol 9 (1986) 153-159
13. Ward C.D., Trombley I.K., Calne D.B., and Kopin I.J. l-dopa decarboxylation in chronically treated patients. Neurology 34 (1984) 198-201
14. Melamed E., and Hefti F. Mechanism of action of short- and long-term l-dopa treatment in parkinsonism: role for the surviving nigrostriatal dopaminergic neurons. Adv Neurol 40 (1984) 149-157
15. Doller H.J., and Connor J.D. Changes in neostriatal dopamine concentrations in response to levodopa infusions. J Neurochem 34 (1980) 1264-1269
16. Leenders K.L., Palmer A.J., Quinn N., Clark J.C., Firnau G., Garnett E.S., et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron tomography. J Neurol Neurosurg Psychiatry 49 (1986) 853-860
17. Zappia M., Olivieri R.L., Bosco D., Nicoletti G., Branca D., Caracciolo M., et al. The long-duration response to l-dopa in the treatment of PD. Neurology 54 (2000) 1910-1915
18. Contin M., Riva R., Martinelli P., Cortelli P., Albani F., and Baruzzi A. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 43 (1993) 367-371
19. Chan P.L., Nutt J.G., and Holford N.H. Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 32 (2005) 459-484
20. LeWitt P.A. Extending the action of levodopa's effects. In: LeWitt P.A., and Oertel W.H. (Eds). Parkinson's disease: The treatment options (1999), Martin Dunitz, London 141-158
21. Carter J.H., Nutt J.G., Woodward W.R., Hatcher L.F., and Trotman T.L. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 39 (1989) 552-556
22. Melamed E., Bitton V., and Zelig O. Episodic unresponsiveness to single doses of l-dopa in parkinsonian fluctuators. Neurology 36 (1986) 100-103
23. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19 (2004) 997-1005
24. Camp D.M., Loeffler D.A., and LeWitt P.A. Levodopa does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem 74 (2000) 1229-1240
25. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
26. Chan P.L., Nutt J.G., and Holford N.H. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm Res 24 (2007) 791-802
27. Brooks D.J., Frey K.A., Marek K.L., Oakes D., Paty D., Prentice R., et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184 suppl 1 (2003) S68-S79
28. Nutt J.G., LeWitt P.A., Ellenbogen A., Wang S., Nguyen T., Khor S.P., et al. Comparison of immediate- and extended-release (IR+ER) carbidopa/levodopa formulations (VADOVA IR+ER) with IR carbidopa/levodopa and controlled-release (CR) carbidopa/levodopa in Parkinson's disease (PD). Mov Disord 22 suppl 16 (2007) S223
29. Reichman A., Yaar A., Kushnir M., and Heldman E. Steady l-DOPA blood levels via transdermal delivery of l-DOPA prodrugs: a novel skin patch for the treatment of Parkinson's disease. Mov Disord 21 suppl 15 (2006) S551
30. Djaldetti R., Treves T.A., Merims D., Sroka H., and Melamed E. Effect of late initiation of levodopa treatment in patients with long-standing Parkinson's disease. Clin Neuropharmacol 26 (2003) 24-27
31. Blindauer K., Shoulson I., Oakes D., Kieburtz K., Schwid S., Fahn S., et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 63 (2006) 210-216
32. Nyholm D., Nilsson R.A., Dizdar N., Constantinescu R., Holm-berg B., Jansson R., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64 (2005) 216-223
33. Stover N.P., Bakay R.A., Subramanian T., Raiser C.D., Cornfeldt M.L., Schweikert A.W., et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol 62 (2005) 1833-1837
34. Carlsson T., Björklund T., and Kirik D. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. Curr Gene Ther 7 (2007) 109-120
35. Misu Y., Kitahama K., and Goshima Y. l-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system. Pharmacol Ther 97 (2003) 117-137
36. Maratos E.C., Jackson M.J., Pearce R.K., Cannizzaro C., and Jenner P. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than l-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol 179 (2003) 90-102
37. Cedarbaum J.M., Gandy S.E., and McDowell F.H. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 41 (1991) 622-629
38. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., and Lang A.E. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58 (2002) 11-17
39. Hornykiewicz O. How does l-dopa work?. In: Barbeau A., and McDowell F.H. (Eds). l-dopa and Parkinsonism (1970), FA Davis, Philadelphia 393-399